DM
GYRE icon

Deerfield Management’s Gyre Therapeutics GYRE Stock Holding History

Deerfield Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-110,747
Closed -$21.4M – 118
2018
Q1 		$21.4M Buy
+110,747
New +$20.7M 0.74% 55
2014
Q2 		– Sell
-783
Closed -$2.93M – 135
2014
Q1 		$2.93M Hold
783
– – 0.12% 105
2013
Q4 		$2.56M Buy
+783
New +$3.09M 0.13% 85

Other funds holding GYRE

ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Deerfield Management's GYRE Position: Q2 2018 in Review

Deerfield Management sold out of Gyre Therapeutics (GYRE) in Q2 2018, closing a stake of 110,747 shares — an estimated $21.4M sold.

Deerfield Management first reported a position in GYRE in Q4 2013 and held it in 3 quarters. The position peaked at $21.4M in Q1 2018. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

  • Deerfield Management reported no remaining Gyre Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Deerfield Management sold 110,747 Gyre Therapeutics shares in Q2 2018, an estimated $21.4M.
  • Deerfield Management first reported a position in Gyre Therapeutics in Q4 2013 and held it in 3 quarters.
  • Deerfield Management's Gyre Therapeutics position peaked at $21.4M in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on Deerfield Management's 13F filing for Q2 2018, filed 14 Aug 2018.